Skip to main content

ChemAxon establishes subsidiary in Basel

| News

ChemAxon establishes subsidiary in Basel

06.11.2020

ChemAxon develops software for application in the chemicals and biopharma industries. Now, the Hungarian company has established a subsidiary in Basel. The customer base and economic conditions were cited as reasons for the choice of location.

The Hungarian company ChemAxon has established the ChemAxon GmbH subsidiary in Basel. The software company chose Basel on account of the connection to customers in the chemicals and biopharma industries as well as the economic conditions. In setting up the new location, it was supported by Basel Area Business & Innovation, the investment and innovation promotion agency (read more about starting a business in Switzerland).

“During the evaluation process and after the incorporation period I was really impressed with all the support and help ChemAxon and I received from BaselArea Business & Innovation,” explains Annamaria Kovacs, the Basel-based representative of ChemAxon.

With headquarters in Budapest, ChemAxon also has offices in the USA, Prague and Asia. Worldwide, ChemAxon has 150 employees. The company’s software products help to accelerate and enhance scientific discovery and collaboration. The solutions are tailored to the requirements of customers in the chemicals and biopharma sectors.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.